Pages that link to "Q26747506"
Jump to navigation
Jump to search
The following pages link to Role of mTOR Inhibitors in Kidney Disease (Q26747506):
Displaying 14 items.
- Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature (Q28067445) (← links)
- Sirt6 deficiency results in progression of glomerular injury in the kidney (Q33563525) (← links)
- Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells (Q41619667) (← links)
- Advances in Chronic Kidney Disease (Q42401109) (← links)
- Mesangial Cell Mammalian Target of Rapamycin Complex 1 Activation Results in Mesangial Expansion. (Q50894283) (← links)
- Rapamycin Nano-Micelle Ophthalmic Solution Reduces Corneal Allograft Rejection by Potentiating Myeloid-Derived Suppressor Cells' Function (Q57817480) (← links)
- Myeloid-Derived Suppressor Cells as a Regulator of Immunity in Organ Transplantation (Q58789294) (← links)
- Tolerogenic Role of Myeloid Suppressor Cells in Organ Transplantation (Q64056560) (← links)
- Knockout of receptor for advanced glycation end-products attenuates age-related renal lesions (Q64109107) (← links)
- Role of Everolimus on Cardiac Functions in Kidney Transplant Recipients (Q87666167) (← links)
- Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges (Q90230633) (← links)
- Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome (Q91813272) (← links)
- Inactivation of TSC1 promotes epithelial-mesenchymal transition of renal tubular epithelial cells in mouse diabetic nephropathy (Q93000511) (← links)
- Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer (Q99350272) (← links)